Search Results - "Kvols, Larry K."

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors by Turaga, Kiran K., Kvols, Larry K.

“…Gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) are relatively rare tumors that arise from the diffuse neuroendocrine system. This heterogeneous group…”
Get full text

Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors by STROSBERG, Jonathan R, CHEEMA, Asima, WEBER, Jill, HAN, Gang, COPPOLA, Domenico, KVOLS, Larry K

“…The American Joint Committee on Cancer (AJCC) staging manual (seventh edition) has introduced its first TNM staging classification for pancreatic…”
Get full text

Prognostic Validity of the American Joint Committee on Cancer Staging Classification for Midgut Neuroendocrine Tumors by STROSBERG, Jonathan R, WEBER, Jill M, FELDMAN, Max, COPPER, Domenico, MEREDITH, Kenneth, KVOLS, Larry K

“…The American Joint Committee on Cancer (AJCC) staging manual has introduced a TNM staging classification for jejunal-ileal (midgut) neuroendocrine tumors…”
Get full text

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial by Yao, James C, Lombard-Bohas, Catherine, Baudin, Eric, Kvols, Larry K, Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, St Peter, Jessica, Haas, Tomas, Lebwohl, David, Van Cutsem, Eric, Kulke, Matthew H, Hobday, Timothy J, O'Dorisio, Thomas M, Shah, Manisha H, Cadiot, Guillaume, Luppi, Gabriele, Posey, James A, Wiedenmann, Bertram

“…PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral…”
Get full text

The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas by Strosberg, Jonathan R, Coppola, Domenico, Klimstra, David S, Phan, Alexandria T, Kulke, Matthew H, Wiseman, Gregory A, Kvols, Larry K

“…Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. These high-grade…”
Get full text

Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience by Wong, Joyce, M.D, Fulp, William J., Ph.D, Strosberg, Jonathan R., M.D, Kvols, Larry K., M.D, Centeno, Barbara A., M.D, Hodul, Pamela J., M.D

“…Abstract Background Staging for pancreatic neuroendocrine tumors (PNET) considers tumor size and lymph node (LN) status; however, correlation with survival…”
Get full text

A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract by Strosberg, Jonathan R, Cheema, Asima, Kvols, Larry K

“…Treatment options for metastatic gastroenteropancreatic neuroendocrine tumors (NETs) have evolved in recent years. The somatostatin analogs octreotide and…”
Get more information

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings by de Jong, Marion, Valkema, Roelf, Jamar, Francois, Kvols, Larry K., Kwekkeboom, Dik J., Breeman, Wout A.P., Bakker, Willem H., Smith, Chuck, Pauwels, Stanislas, Krenning, Eric P.

“…In preclinical studies in rats we evaluated biodistribution and therapeutic effects of different somatostatin analogs, [ 111In-DTPA]octreotide, [ 90Y-DOTA, Tyr…”
Get full text

Phase II Study of 5‐fluorouracil, Doxorubicin, and Mitomycin C for Metastatic Small Bowel Adenocarcinoma by Gibson, Michael K., Holcroft, Christina A., Kvols, Larry K., Haller, Daniel

“…Background. Small bowel adenocarcinoma is a rare gastrointestinal malignancy that is treated primarily with surgery. Even with optimal resection, however,…”
Get full text

Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors by Kvols, Larry K, Woltering, Eugene A

“…The somatostatin analogs octreotide, lanreotide and RC-160 (vapreotide) are known to have direct and indirect antitumor effects. Direct effects include the…”
Get full text

GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumors by van der Zwan, Wouter A, Bodei, Lisa, Mueller-Brand, Jan, de Herder, Wouter W, Kvols, Larry K, Kwekkeboom, Dik J

“…Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors…”
Get full text

Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine Tumors: An Analysis of the AJCC and ENETS Staging Classifications by STROSBERG, Jonathan R, CHEEMA, Asima, WEBER, Jill M, GHAYOURI, Masoumeh, GANG HAN, HODUL, Pamela J, KVOLS, Larry K

“…The risk of metastatic spread among patients with early-stage pancreatic neuroendocrine tumors has not been well established. The authors sought to evaluate…”
Get full text

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study by Kvols, Larry K, Oberg, Kjell E, O'Dorisio, Thomas M, Mohideen, Pharis, de Herder, Wouter W, Arnold, Rudolf, Hu, Ke, Zhang, Yilong, Hughes, Gareth, Anthony, Lowell, Wiedenmann, Bertram

“…Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and…”
Get full text

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship by Barone, Raffaella, Borson-Chazot, Françoise, Valkema, Roelf, Walrand, Stéphan, Chauvin, Franck, Gogou, Lida, Kvols, Larry K, Krenning, Eric P, Jamar, François, Pauwels, Stanislas

“…Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog…”
Get full text

Survival and Response After Peptide Receptor Radionuclide Therapy With [ 90Y-DOTA 0,Tyr 3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors by Valkema, Roelf, Pauwels, Stanislas, Kvols, Larry K., Barone, Raffaella, Jamar, Francois, Bakker, Willem H., Kwekkeboom, Dik J., Bouterfa, Hakim, Krenning, Eric P.

“…Because the role of chemotherapy, interferon, or somatostatin analogs as antiproliferative agents is uncertain, currently few treatment options exist for…”
Get full text

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate by Valkema, Roelf, Pauwels, Stanislas A, Kvols, Larry K, Kwekkeboom, Dik J, Jamar, Francois, de Jong, Marion, Barone, Raffaella, Walrand, Stephan, Kooij, Peter P M, Bakker, Willem H, Lasher, Janet, Krenning, Eric P

“…The kidneys are critical organs in peptide receptor radiation therapy (PRRT). Renal function loss may become apparent many years after PRRT. We analyzed the…”
Get full text

Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets by Kvols, Larry K

“…The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the tumor compared with normal tissue. It would have…”
Get full text

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs by Pauwels, Stanislas, Barone, Raffaella, Walrand, Stéphan, Borson-Chazot, Françoise, Valkema, Roelf, Kvols, Larry K, Krenning, Eric P, Jamar, François

“…The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk…”
Get full text

Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs by Kwekkeboom, Dik J, Mueller-Brand, Jan, Paganelli, Giovanni, Anthony, Lowell B, Pauwels, Stanislas, Kvols, Larry K, O'Dorisio, Thomas M, Valkema, Roelf, Bodei, Lisa, Chinol, Marco, Maecke, Helmut R, Krenning, Eric P

“…A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is the use of radiolabeled somatostatin analogs. Initial studies with…”
Get full text

Revisiting C.G. Moertel's land of small tumors by Kvols, Larry K

Get full text